AstraZeneca says expanded use of lung cancer drug backed by EU agency

LONDON (Reuters) - British pharmaceutical company AstraZeneca said on Friday an expanded use of its IRESSA treatment for lung cancer has been recommended for approval by European regulators. The company said a label update to IRESSA meant the treatment would now be able to be applied after blood-based testing. Previously a patient had to provide a tumour sample before receiving the treatment. "If doctors are unable to assess the mutation status of atumour, then patients' access to potentially life-changing medicines such as IRESSA becomes restricted. ...



via Health News Headlines - Yahoo News http://ift.tt/Ygef6G